{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:12:57Z","timestamp":1778155977422,"version":"3.51.4"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.ejogrb.2005.10.005","type":"journal-article","created":{"date-parts":[[2005,11,10]],"date-time":"2005-11-10T07:17:48Z","timestamp":1131607068000},"page":"152-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Current treatment issues in female hyperprolactinaemia"],"prefix":"10.1016","volume":"125","author":[{"given":"Pier Giorgio","family":"Crosignani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2005.10.005_bib1","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2002-36709","article-title":"Hyperprolactinemia: etiology, diagnosis, and management","volume":"20","author":"Mah","year":"2002","journal-title":"Seminars Reprod Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrc926","article-title":"The pathogenesis of pituitary tumours","volume":"2","author":"Asa","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib4","first-page":"851","article-title":"Management of psychotropic-induced hyperprolactinemia","volume":"11","author":"Marken","year":"1992","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib5","first-page":"575","article-title":"Diagnosis and management of hyperprolactinemia","volume":"169","author":"Serri","year":"2003","journal-title":"CMAJ"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00024677-200302010-00003","article-title":"Hyperprolactinemia: pathophysiology and management","volume":"2","author":"Verhelst","year":"2003","journal-title":"Treat Endocrinol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2265.1992.tb02340.x","article-title":"Characterization of big, big prolactin in patients with hyperprolactinaemia","volume":"37","author":"Leite","year":"1992","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib9","first-page":"119","article-title":"Macroprolactin-a cause of pseudohyperprolactinaemia","volume":"9","author":"Yuen","year":"2003","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1055\/s-0029-1211358","article-title":"Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL\u2013IgG complex","volume":"103","author":"Bonhoff","year":"1995","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jcem.87.2.8272","article-title":"Macroprolactinemia revisited: a study on 106 patients","volume":"87","author":"Vallette-Kasic","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2265.2003.01852.x","article-title":"Clinical and radiological features of patients with macroprolactinaemia","volume":"59","author":"Strachan","year":"2003","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF03343542","article-title":"Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays","volume":"22","author":"Cavaco","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib14","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1210\/jc.2004-2234","article-title":"The impact on clinical practice of routine screening for macroprolactin","volume":"90","author":"Gibney","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib15","first-page":"193","article-title":"Prolactin levels in the polycystic ovary syndrome","volume":"29","author":"Milewicz","year":"1984","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1530\/rep.0.1230497","article-title":"Behavioural significance of prolactin signalling in the central nervous system during pregnancy and lactation","volume":"123","author":"Grattan","year":"2002","journal-title":"Reproduction"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000292379","article-title":"Sustained prolactin release associated with precocious ovarian failure","volume":"39","author":"Crosignani","year":"1995","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib18","first-page":"1085","article-title":"Clinical presentation of hyperprolactinemia","volume":"44","author":"Luciano","year":"1999","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib19","first-page":"1075","article-title":"Guidelines for the diagnosis and treatment of hyperprolactinemia","volume":"44","author":"Biller","year":"1999","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib20","first-page":"65","article-title":"Prevalence of hyperprolactinemia in anovulatory women","volume":"56","author":"Greer","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib21","first-page":"1775","article-title":"Clinical review 106: amenorrheic bone loss","volume":"84","author":"Miller","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","article-title":"Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism","volume":"110","author":"Greenspan","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1210\/jcem-56-6-1120","article-title":"Bone density in amenorrheic women with and without hyperprolactinemia","volume":"56","author":"Schlechte","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bmj.324.7332.250","article-title":"Hyperprolactinaemia caused by antipsychotic drugs","volume":"324","author":"Wieck","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1210\/jcem-59-6-1050","article-title":"Vertebral body bone mineral content in hyperprolactinemic women","volume":"59","author":"Koppelman","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib26","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/gye.15.1.43.47","article-title":"Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women","volume":"15","author":"Vartej","year":"2001","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2002.01510.x","article-title":"Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas?","volume":"56","author":"Yermus","year":"2002","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib30","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0015-0282(16)57054-X","article-title":"Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study","volume":"62","author":"Vercellini","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","article-title":"Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males","volume":"83","author":"Di Somma","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib32","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s002340050340","article-title":"MRI of microadenomas in patients with hyperprolactinaemia","volume":"38","author":"Rand","year":"1996","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.fertnstert.2005.01.102","article-title":"Pituitary imaging is indicated for the evaluation of hyperprolactinemia","volume":"84","author":"Bayrak","year":"2005","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib34","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1210\/jc.2001-011943","article-title":"Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-2265.1999.00757.x","article-title":"Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition","volume":"51","author":"Olukoga","year":"1999","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib37","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bmj.286.6372.1177","article-title":"Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia","volume":"286","author":"Franks","year":"1983","journal-title":"Brit Med J (Clin Res Ed)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib38","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.90.19.8861","article-title":"Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies","volume":"90","author":"Levey","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib39","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib40","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/j.1476-5381.1991.tb12354.x","article-title":"Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells","volume":"103","author":"Schoors","year":"1991","journal-title":"Brit J Pharmacol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0163-7258(98)00027-8","article-title":"Renal dopamine receptors in health and hypertension","volume":"80","author":"Jose","year":"1998","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10641969709080813","article-title":"Dopamine and sympathoadrenal activity in man","volume":"19","author":"Mannelli","year":"1997","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00003081-200306000-00013","article-title":"Dopamine agonist therapy for hyperprolactinemia","volume":"46","author":"Bankowski","year":"2003","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","article-title":"Drugs 5 years later. Bromocriptine","volume":"100","author":"Vance","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib45","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1034\/j.1600-0412.2001.080002162.x","article-title":"Long-term follow-up of 246 hyperprolactinemic patients","volume":"80","author":"Touraine","year":"2001","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib47","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1210\/jcem-60-4-764","article-title":"Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal","volume":"60","author":"Moriondo","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib48","first-page":"524","article-title":"Efficacy and safety of bromocriptine in the treatment of macroprolactinomas","volume":"63","author":"Essais","year":"2002","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib49","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib50","first-page":"320","article-title":"Impact of once- and twice-daily dosing regimens on adherence and overall safety","volume":"14","author":"Hawkins","year":"2004","journal-title":"AIDS Reader"},{"issue":"Suppl 1","key":"10.1016\/j.ejogrb.2005.10.005_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/095646203322491815","article-title":"Once-daily therapy: less is more","volume":"14","author":"Moyle","year":"2003","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib52","first-page":"592","article-title":"Overview of patient compliance with medication dosing: a literature review","volume":"6","author":"Greenberg","year":"1984","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib53","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib54","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-63-4-941","article-title":"Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients","volume":"63","author":"Ferrari","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib55","first-page":"2338","article-title":"Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline","volume":"81","author":"Biller","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib56","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib57","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1210\/jcem-69-4-725","article-title":"Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients","volume":"69","author":"Ciccarelli","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib58","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib59","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","article-title":"Treatment of macroprolactinoma with cabergoline: a study of 85 patients","volume":"46","author":"Ferrari","year":"1997","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib60","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF03348017","article-title":"Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy","volume":"20","author":"Ciccarelli","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/jnnp.68.6.685","article-title":"Dopamine agonists: their role in the treatment of Parkinson's disease","volume":"68","author":"Brooks","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/09513599809029348","article-title":"Endocrine effects of CV 205\u2013502, a new dopamine agonist, in hyperprolactinemic women","volume":"2","author":"van der Heijden","year":"1988","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib63","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0015-0282(16)60966-4","article-title":"The effectiveness, safety, and tolerability of CV 205\u2013502 in hyperprolactinemic women: a 12-month study","volume":"52","author":"van der Heijden","year":"1989","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib64","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","article-title":"A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205\u2013502, with bromocriptine in women with hyperprolactinaemia","volume":"32","author":"Homburg","year":"1990","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib65","first-page":"449","article-title":"Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205\u2013502","volume":"39","author":"Glaser","year":"1994","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","article-title":"CV 205\u2013502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia","volume":"40","author":"van der Heijden","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib67","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1210\/jcem-72-5-1136","article-title":"The efficacy and tolerability of CV 205\u2013502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine","volume":"72","author":"van der Lely","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1012884214668","article-title":"Quinagolide in the management of prolactinoma","volume":"3","author":"Schultz","year":"2000","journal-title":"Pituitary"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib69","first-page":"411","article-title":"Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l\u2019Hypophyse","volume":"61","author":"Rohmer","year":"2000","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/eje.0.1350413","article-title":"Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy","volume":"135","author":"Morange","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2265.1991.tb01731.x","article-title":"Effect of the new dopaminergic agonist CV 205\u2013502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas","volume":"34","author":"Duranteau","year":"1991","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","article-title":"The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas","volume":"53","author":"Di Sarno","year":"2000","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib73","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","article-title":"A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"14","author":"Webster","year":"1996","journal-title":"Drug Safety"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib74","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2265.1994.tb02799.x","article-title":"Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine","volume":"41","author":"Vilar","year":"1994","journal-title":"Clin Endocrinol (Oxford)"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/09513599409072452","article-title":"Positive response to compound CV 205\u2013502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine","volume":"8","author":"Merola","year":"1994","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib76","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF03343751","article-title":"A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients","volume":"23","author":"De Luis","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib77","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/jcem.83.8.5001","article-title":"Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up","volume":"83","author":"Colao","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib78","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF03344963","article-title":"A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients","volume":"17","author":"Giusti","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib79","unstructured":"Parlodel tablets (bromocriptine). United Kingdom summary of product characteristics, 2004."},{"key":"10.1016\/j.ejogrb.2005.10.005_bib80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1185\/03007998609110437","article-title":"The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review","volume":"10","author":"Weil","year":"1986","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib81","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","article-title":"Pregnancy outcome after treatment with the ergot derivative, cabergoline","volume":"10","author":"Robert","year":"1996","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib82","series-title":"Manifestations, epidemiology and pathogenesis of prolactinomas in women","first-page":"67","year":"1986"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib83","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1471-0528.1984.tb04859.x","article-title":"Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine. Case reports","volume":"91","author":"Crosignani","year":"1984","journal-title":"Brit J Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib84","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0020-7292(86)90099-8","article-title":"Rapid regression through bromocriptine therapy of a suprasellar extending prolactinoma during pregnancy","volume":"24","author":"Tan","year":"1986","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib85","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/oxfordjournals.humrep.a137010","article-title":"Is pregnancy the best treatment for hyperprolactinaemia?","volume":"4","author":"Crosignani","year":"1989","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib86","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1530\/eje.0.1340454","article-title":"Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine","volume":"134","author":"Delgrange","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib87","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","article-title":"Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal","volume":"87","author":"Passos","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib88","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3171\/jns.1995.82.5.0886","article-title":"Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report","volume":"82","author":"Kovacs","year":"1995","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib89","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-8140(96)91807-1","article-title":"Role of radiation therapy in clinical hormonally-active pituitary adenomas","volume":"41","author":"Tsang","year":"1996","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib91","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/bmj.318.7193.1226","article-title":"Management of pituitary tumours","volume":"318","author":"Bevan","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib92","first-page":"628","volume":"31","author":"Clayton","year":"1997","journal-title":"J R Coll Physicians Lond"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib93","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1210\/jcem.82.4.3845","article-title":"The case for initial surgical removal of certain prolactinomas","volume":"82","author":"Molitch","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib94","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.1993.00410160017001","article-title":"Adherence to treatment and health outcomes","volume":"153","author":"Horwitz","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib95","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0149-2918(97)80018-5","article-title":"Variations in compliance among hypertensive patients by drug class: implications for health care costs","volume":"19","author":"Rizzo","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib96","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00006454-199702001-00008","article-title":"Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of acute otitis media","volume":"16","author":"Wandstrat","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib97","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0027-5107(89)90040-7","article-title":"Case-control cytogenetic study in offspring of mothers treated with bromocriptine during early pregnancy","volume":"210","author":"Czeizel","year":"1989","journal-title":"Mutat Res"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib98","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000180100","article-title":"Follow-up of children born of bromocriptine-treated mothers","volume":"22","author":"Raymond","year":"1985","journal-title":"Horm Res"},{"key":"10.1016\/j.ejogrb.2005.10.005_bib99","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","article-title":"Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size","volume":"34","author":"van\u2019t Verlaat","year":"1991","journal-title":"Clin Endocrinol (Oxford)"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211505005282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211505005282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:14:53Z","timestamp":1759554893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211505005282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0301211505005282"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2005.10.005","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current treatment issues in female hyperprolactinaemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2005.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}